The US FDA has postponed the March 17, 2015 the Arthritis Advisory Committee (AAC). The Committee meeting was scheduled to discuss the safety and efficacy of CT- P13, a proposed biosimilar to Janssen Biotech Inc.'s Remicade (infliximab), submitted by Celltrion, Inc. The FDA says that the reason for the postponement is that information requests are pending with the sponsor of the application. Tarius will monitor the Federal Register for announcements regarding this meeting.
Back to All Events
Earlier Event: March 9Dermatologic and Ophthalmic Drugs Advisory Committee Meeting
Later Event: March 18CANCELLED: Anesthetic and Analgesic Drug Products Advisory Committee